Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Lucid Cap Mkts

Turn Therapeutics (NASDAQ:TTRX) was upgraded by Lucid Cap Mkts to a “strong-buy” rating in a note issued to investors on Thursday, Zacks reports.

Several other brokerages have also recently weighed in on TTRX. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. WBB Securities reissued a “sell” rating and set a $10.00 price target on shares of Turn Therapeutics in a research report on Monday, September 14th. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Stock Down 1.9%

Shares of Turn Therapeutics stock opened at $13.26 on Thursday. The stock’s 50-day moving average is $10.60 and its 200 day moving average is $6.95. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The firm has a market cap of $394.99 million and a price-to-earnings ratio of -45.72. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current year.

Institutional Trading of Turn Therapeutics

Several hedge funds have recently added to or reduced their stakes in TTRX. Bank of America Corp DE bought a new stake in shares of Turn Therapeutics in the 2nd quarter worth approximately $103,000. Tamar Securities LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth $59,000. Jefferies Financial Group Inc. purchased a new stake in Turn Therapeutics in the second quarter worth $119,000. Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics in the second quarter valued at $242,000. Finally, BlackRock Inc. bought a new stake in shares of Turn Therapeutics in the second quarter valued at $282,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.